Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2014
09/03/2014EP2771356A1 Chimeric molecule involving oligomerized fasl extracellular domain
09/03/2014EP2771351A1 Pat-lm1 epitopes and methods for using same
09/03/2014EP2771350A1 Topk peptides and vaccines including the same
09/03/2014EP2771343A1 Methyltransferase inhibitors for treating cancer
09/03/2014EP2771341A1 Novel compositions and methods for treating cancer
09/03/2014EP2771340A1 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
09/03/2014EP2771337A1 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
09/03/2014EP2771334A1 Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
09/03/2014EP2771329A1 Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
09/03/2014EP2771069A2 Inhibiting g protein coupled receptor 6 kinase polypeptides
09/03/2014EP2771037A2 Therapeutic agents and uses thereof
09/03/2014EP2771014A1 Pharmaceutical composition for elimination of cancer stem cells
09/02/2014US8822647 Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
09/02/2014US8822637 Somatostatin analogues
09/02/2014US8822636 Peptides for activation and inhibition of δPKC
09/02/2014US8822532 Bis[thiohydrazide amide] compounds for treating leukemia
09/02/2014US8822519 Compound with agitation effect on peroxisome proliferator-activated receptor process for its preparation and use thereof
09/02/2014US8822481 Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
09/02/2014US8822468 3-Methyl-imidazo[1,2-b]pyridazine derivatives
09/02/2014US8822458 Substituted oxazolidinones and their use in the field of blood coagulation
09/02/2014US8822442 Somatostatin-dopamine chimeric analogs
09/02/2014US8822422 Antitumor agent
09/02/2014US8822420 Peptides and aptamers thereof as specific modulators of mutant p53 function
09/02/2014US8822405 Uses of mammalian cytokines and agonists; related reagents
09/02/2014US8821913 Controlled releases system containing temozolomide
09/02/2014US8821873 Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
09/02/2014US8821869 Treatment methods using c-Met antibodies
09/02/2014CA2736974C Tumour-associated peptides that bind to mhc molecules
09/02/2014CA2602467C Bcrp/abcg2 inhibitor
09/02/2014CA2578549C Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
09/02/2014CA2413866C Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
08/2014
08/28/2014WO2014130992A1 Methods and agents for preventing and treating plasma cell dyscrasias
08/28/2014WO2014130823A1 Dendritic cell enhancement of protection by human muc1-stimulated mononuclear cells against cancer
08/28/2014WO2014130657A1 Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
08/28/2014WO2014130572A1 Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators
08/28/2014WO2014130540A1 Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
08/28/2014WO2014130470A1 Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
08/28/2014WO2014130310A1 Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
08/28/2014WO2014130016A1 Drug combinations to treat liver cancer
08/28/2014WO2014129969A1 Therapeutic agents
08/28/2014WO2014129914A1 Methods of treatment
08/28/2014WO2014128701A1 Interferon treatment targeting mutant p53 expressing cells
08/28/2014WO2014128655A1 Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
08/28/2014WO2014128612A1 Quinazolin-4-one derivatives
08/28/2014WO2014128588A1 Solid forms of a selective cdk4/6 inhibitor
08/28/2014WO2014128524A1 An improved process for preparation of an intermediate of the pyrrolidine substituted flavones
08/28/2014WO2014128523A1 A process for preparation of an intermediate of the pyrrolidine substituted flavones
08/28/2014WO2014128504A1 Inactive n-acetylated-alpha-linked acidic dipeptidase-like protein 2 (naaladl2) as a therapeutic and diagnostic target
08/28/2014WO2014128487A1 Treatment of cancer
08/28/2014WO2014128465A1 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase
08/28/2014WO2014128258A1 Caix stratification based cancer treatment
08/28/2014WO2014128245A1 Dna hypomethylating agents for cancer therapy
08/28/2014WO2014128225A1 Activation of inkt cells
08/28/2014WO2014128221A1 A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
08/28/2014WO2014128198A1 Bilaterally-substituted tricyclic compounds for the treatment of human immunodeficiency virus type-1 (hiv-1) infection and other diseases
08/28/2014WO2014128127A1 Methods and pharmaceutical compositions for treatment of prostate cancer
08/28/2014WO2014128093A1 Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
08/28/2014WO2014127478A1 Vaccine composition
08/28/2014WO2014106492A3 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
08/28/2014WO2014089335A3 Bcma antigen binding proteins
08/28/2014WO2013134288A9 Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
08/28/2014US20140243284 Biologically active macrolides, compositions, and uses thereof
08/28/2014US20140242192 Clusterin Antisense Therapy for Treatment of Cancer
08/28/2014US20140242094 Methods related to tim 3, a th1-specific cell surface molecule, for activating antigen presenting cells
08/28/2014US20140242089 Glycoproteins having lipid mobilising properties and therapeutic applications thereof
08/28/2014US20140242086 Polynucleotides encoding signal peptide-containing molecules
08/27/2014EP2769976A1 Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
08/27/2014EP2769733A1 Stabilised mRNA encoding MUC1 against cancer
08/27/2014EP2769730A1 Treatment method for dissolving tumour and transforming cancer cells with phenol and quinone
08/27/2014EP2769727A1 Use for deoxynucleoside/nucleoside combination in preparation of tumor medicament
08/27/2014EP2768863A1 Anti-cd22 chimeric antigen receptors
08/27/2014EP2768852A1 Peptide compounds derived from melanotransferrin and uses thereof
08/27/2014EP2768849A1 Novel plant defensins and use in the treatment of proliferative diseases
08/27/2014EP2768841A1 Acid addition salts of 5beta -hydroxy-6alpha -[2-(1h-imidazol-4-yl)ethylamino]cholestan-3beta -ol
08/27/2014EP2768824A2 Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
08/27/2014EP2768820A2 A process for making an intermediate of cabazitaxel
08/27/2014EP2768813A1 Quinazoline derivatives as pi3k modulators
08/27/2014EP2768799A1 Substituted biaryl alkyl amides
08/27/2014EP2768534A1 Antigen presenting cancer vaccine
08/27/2014EP2768524A1 Pd-l1 based immunotherapy
08/27/2014EP2768519A2 Antigen presenting cancer vaccine with gamma interferon
08/27/2014EP2768513A2 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
08/27/2014EP2768512A1 Enzyme inhibitor for cancer treatment
08/27/2014EP2768510A1 Camalexin as a treatment for prostate cancer
08/27/2014EP2768498A1 Therapeutic combination for the treatment of cancer
08/27/2014EP2768493A1 Phytocannabinoids for use in the treatment of breast cancer
08/27/2014EP2768491A1 Inhibitors of arginase and their therapeutic applications
08/26/2014US8816082 Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
08/26/2014US8815840 Carbazole and carboline kinase inhibitors
08/26/2014US8815823 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
08/26/2014US8815821 Double-stranded oligonucleotides
08/26/2014US8815805 Formulations having an antagonist of α5β1 for anti-angiogenesis and cancer treatment
08/26/2014US8815801 Controlled release composition and method of producing the same
08/26/2014US8815256 Induction of tumor immunity by variants of folate binding protein
08/26/2014US8815241 Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
08/26/2014US8815238 Methods for Preparing TACI-immunoglobulin fusion proteins
08/26/2014CA2691539C Modified toxins
08/26/2014CA2656618C Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
08/26/2014CA2614080C Anti-ccr7 receptor antibodies for the treatment of cancer
08/26/2014CA2582252C Therapeutic use of anti-tf-antigen antibody
1 ... 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 ... 2211